Medical researchers are always looking for ways in which they can eliminate illnesses and improve the overall quality of human life. Companies and governments have realized the importance of making sure that the ailments that are a menace to the human race have been eliminated within the century. One of the companies that have been leading in medical research is Amphivena Therapeutics according to LinkedIn. The company has been dealing with looking for therapies and treatments that work in the elimination of all manner of hematologic malignancies.
JeanMarie Guenot works at Amphivena. She has been working in medical research for the longest time. She has a Bachelor’s degree and an MBA from the Wharton School in the University of California. She also has a PhD from the University of California in San Francisco. When she started her career, she was working as a principal scientist at Hoffman-La-Roche. She was in charge of coordination of all the research into many types of metabolic disorders. She then got another job at Atlas ventures. Here, she was in charge of the financial side of the research center. Jeanmarie Guenot coordinated the venture capital investments and arranged for the funding of various companies that were researching about life science. She has done extensive research on autoimmune diseases, inflammation and oncology.
There was also a time that she was working with the SKS Ocular. The organization researches and looks for treatments to disorders like glaucoma and macular degeneration on Crunchbase. She has also been a financial advisor at Hoffman-La-Roche. All these are experiences that have molded her for her present role. It is therefore understandable that she is helping the current company she is heading in making the strides that they are making in their business.
Jeanmarie Guenot says that one of the goals that she is most passionate about achieving is making sure that she gets all the experience that she needs to change the lives of the entire humanity for the best. JeanMarie is an inspiration to the scientists, the medical fraternity and everyone else in general. It is her hope that she will get treatment for hematologic malignancies during her tenure at the current company at http://amphivena.com/amphivena_leaders/jeanmarie-guenot-ph-d/.